Cowen’s healthcare analyst Boris Peaker came out with an update on Celldex Therapeutics (NASDAQ:CLDX), following yesterday’s news that the company and partner Bristol Myers-Squibb initiated a phase 1/2 …
Cowen analyst Boris Peaker weighed in today with his thoughts on Keryx Biopharmaceuticals (NASDAQ:KERX), following the news that the FDA approved Rockwell Medical’s (NASDAQ:RMTI) Triferic …
In a research report sent to investors, Cowen analyst Boris Peaker reiterated an Outperform rating on Curis Inc. (NASDAQ:CRIS), following the news that …
In a research report issued today, Cowen analyst Boris Peaker reiterated an Outperform rating on Celldex Therapeutics (NASDAQ:CLDX) with a $26 price target. …
Cowen analyst Boris Peaker maintained an Outperform rating on Idera Pharmaceuticals (NASDAQ:IDRA), as the company announced that data for its lead product candidate IMO-8400 …
Cowen analyst Boris Peaker reiterated an Outperform rating on MEI Pharma (NASDAQ:MEIP), as the company reported clinical activity from a Phase II study of …
Cowen analyst Boris Peaker maintained an Outperform rating on Celldex Therapeutics (NASDAQ:CLDX) with a price target of $26, following the news that the …
In a research report sent to investors today, Cowen analyst Boris Peaker initiated coverage on Keryx Biopharmaceuticals (NASDAQ:KERX) with an Outperform rating and a $25 …
In a research report sent to investors today, Cowen analyst Boris Peaker maintained an Outperform rating on Idera (NASDAQ:IDRA), while no price target …
